OneOme, co-founded by Mayo Clinic, is working to deliver the most comprehensive, cost-effective pharmacogenomic testing and tools for all providers across the globe to use in everyday patient care. By increasing adoption of pharmacogenomics, OneOme may help providers make better prescription decisions, protect patients from adverse drug reactions and drug ineffectiveness, and reduce healthcare costs.
MINNEAPOLIS (February 20, 2018) – OneOme, a healthcare technology company whose genetic test helps predict how a person will respond to hundreds of medications and enables healthcare providers to prescribe more effective medications, today announced that it is included in Fast Company’s annual ranking of the 50 Most Innovative Companies for 2018.
MINNEAPOLIS (January 10, 2018) – Precision medicine company OneOme is partnering with PWNHealth to increase patient access to the RightMed® comprehensive test without compromising patient safety.
MINNEAPOLIS (November 16, 2017) – Last night, OneOme was awarded a Tekne Award in Healthcare at the 18th Annual Minnesota High Tech Association (MHTA) Tekne Awards. The Tekne Awards honor companies and individuals in Minnesota who have demonstrated superior technology innovation and leadership. OneOme’s RightMed® pharmacogenomic solution leads the way in personalized medicine by identifying how a patient's DNA and current medications may affect their response to medications.
MINNEAPOLIS (October 26, 2017) – The Concierge Medicine Forum held this week in Atlanta will feature an expert on pharmacogenomics from OneOme, a leading precision medicine company. Ryan Gregg, Ph.D, medical science liaison from OneOme, will present a session on pharmacogenomics on Friday, October 27, at 11:05 a.m. at the Forsyth Conference Center in Cumming, Georgia. Pharmacogenomics is an emerging field that identifies how a patient's unique DNA and current medications may affect their response to medications.
SINGAPORE, MINNEAPOLIS (October 11, 2017) – In Singapore, OneOme and Tucker Medical are working together to help improve preventive care and oncology treatments. OneOme is a leader in pharmacogenomic testing and Tucker Medical is a multi-specialty practice offering personalized medicine and care in medical oncology, gastroenterology, and family medicine.
MINNEAPOLIS (October 10, 2017) – Today, OneOme announced it has been named a finalist for the 18th Annual Minnesota High Tech Association (MHTA) Tekne Awards in the Healthcare category. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and leadership. OneOme’s RightMed® pharmacogenomic solution identifies how a patient's DNA and current medications may affect their response to medications.
If you are interested in being a part of the future of precision medicine and would like to discuss investment opportunities with OneOme, please contact us at INVEST@ONEOME.COM.
John L. Black III, M.D. is one of the co-founders of OneOme and also a consultant in the Division of Clinical Biochemistry and Immunology with a joint appointment in the Department of Psychiatry and Psychology at Mayo Clinic in Rochester. He joined the staff of Mayo Clinic in 1985 and is currently the co-director of the Personalized Genomics Laboratory. He received his B.A. and M.S. in psychology from the University of Wyoming. He received his M.D. (cum laude) from Creighton University School of Medicine. He is board certified in general, geriatric, and addiction psychiatry and is a clinical chemist.
Paul joined OneOme as its President and COO in August 2015 and became CEO in June of 2016. Prior to OneOme, Paul led global commercialization for Invitae, a San Francisco-based hereditary disease diagnostics company that is listed on the New York Stock Exchange and that raised over $120Million in capital during Paul’s tenure. Prior to Invitae, Paul served as Vice Chair of Global Business Development for Mayo Clinic and was the leader of Mayo Medical Laboratories’ global commercial team – one of the world’s largest full-service reference labs. Prior to that, Paul held leadership roles at what is now Zimmer-Biomet and at Boston Scientific, both highly competitive, cutting-edge, and fast-paced organizations. Paul received his B.S. in business administration from the University of Wisconsin – Stout.
Jason is the Chief Technology Officer with over 20 years of Healthcare Information Technology experience. Prior to joining OneOme, Jason held the position of IT Section Head at Mayo Clinic and was responsible for leading their IT strategy for genomics, informatics and advanced analytics. In addition, he was the Associate Director of IT for Mayo Clinic’s Center for Individualized Medicine. Jason holds a B.S. in molecular biology from University of Wisconsin – Eau Claire and a M.A. in Healthcare Administration from St. Mary’s University of Minnesota.
Mark is currently the Chief Financial Officer (CFO) for OneOme and Invenshure, LLC. Previously, Mark was the CFO at The Emily Program, where he oversaw accounting, finance, payroll, and financial analytics. During his tenure, Mark sat on the board of directors, was a member of the senior leadership team, structured a debt and equity recapitalization, and was instrumental in business development during a period of rapid growth. Mark received his J.D. from the University of St. Thomas School of Law and B.A. from Saint John’s University.
Brian joined OneOme as the Director of Commercial Operations in October 2015. Previously, he held management roles in operations, analytics, and IT for a genetic information company, diagnostic reference laboratory, and an integrated health system. Brian has a B.S. in marketing from Winona State University and an M.B.A. from the University of Wisconsin — La Crosse.
Don joined the OneOme team in May of 2016 as Director of East Sales and after making significant progress advancing OneOme's commercial efforts was subsequently promoted to Vice President of North American Sales and Business Development. Don has spent the past 15 years of his career in various commercial roles within genetic technology and services sectors including roles most recently at the Broad Institute where he helped launch Broad Genomic Services and at Complete Genomics, Sequenom, and Invitrogen/Life Technologies/Thermo Fisher prior to that. Don received his PhD in pharmacology and neuroscience from the University of Nebraska Medical Center and his MBA from the University of Nebraska Omaha.
Jason is the Director of Product Development at OneOme. He is also the Director of Operations at Invenshure, LLC and is a technical leader with diverse product development experience, outstanding customer and engineering management skills, and a proven ability to build consensus and motivate teams to excel. Previously, he was the Vice President of Products for Logic PD, and before that he was Director of Electrical Engineering. Jason has a B.S. in physics from Bethel University and an M.S. in mechanical engineering from the University of Minnesota — Twin Cities.
Bronwyn is the founder of Phoenix Laboratory Consulting, based in Prospect, Kentucky. She has 15 years of experience in molecular genetics, with expertise in the design and validation of laboratory-developed tests, high-complexity clinical laboratory operations, quality systems, regulatory compliance, and medical device software. Her pharmacogenetics specialties include CYP450 haplotype and copy number analysis, data interpretation, and reporting. She earned her B.S. in Biology at Trinity University and her Ph.D. at Indiana University, followed by a postdoctoral fellowship in microbial pathology at the University of Iowa.
Ross Higgins joined OneOme in early 2016 and holds responsibility for organizing and directing laboratory operations for the company. Most recently, Ross served in a dual business development and product management role for Douglas Scientific, where he was responsible for driving both product development and market expansion efforts. Ross also brings extensive experience in the clinical laboratory field, owing to several years managing the molecular genetics department at a large, CAP-accredited reference laboratory. Ross has a B.S. in Clinical Laboratory Sciences and an M.B.A. from Virginia Commonwealth University. He also maintains ASCP certification as a Medical Laboratory Scientist.
Mark leads pharmacogenomics program development for OneOme, focusing on plan sponsors and PBMs. He has worked in many facets of healthcare including health plans, hospitals and clinics, PBMs, pharmacies, consulting and marketing firms, and technology startups. Most recently, Mark served as Director of Product Development within Specialty Pharmacy for OptumRx. Previously, with Intellogy Health Designs, he consulted on a wide variety of projects with US Oncology, Teradata, Fujitsu, McKesson/Relay Health, Rocky Mountain Cancer Centers and more. Mark received his B.S. in health and medical marketing from the University Wisconsin-Superior.
Troy is the co-founder and chairman of the board of OneOme. He is also a co-CEO, co-founder, and managing partner of Invenshure. Previously, he was the President and Chief Financial Officer at Steady State Imaging, where he was instrumental in developing a commercialization strategy that helped guide the sale of the company to GE Healthcare in 2011. Troy holds a B.S. in electrical engineering from the University of Minnesota as well as a B.A. in physics and a B.A. in engineering science from Bethel College.
Harlan serves as a member of OneOme’s board. His career has included Sr. Management positions in for-profit and not-for-profit healthcare organizations. Most recently, Harlan managed the outpatient pharmacies, specialty pharmacy and retail medical supply businesses at Mayo Clinic in Rochester MN. Previously, Harlan held Sr. level management positions at a number of start-up healthcare companies including Quantum Health Resources and Caremark. Harlan has a B.S. in Pharmacy from South Dakota State University.
Jeremy is managing partner at Invenshure, an early-stage venture firm based in Minneapolis, and helped launch OneOme, for which he now serves as a director. He is an active investor and board member in the diagnostics and genomics arenas. Jeremy was an interventional radiologist at Mayo Clinic, where he also served as Associate Chair of the Department of Radiology and ran business development for Mayo Global Business Solutions. Jeremy earned his M.D. at Mayo Medical School and completed surgery and radiology training at Mayo Clinic and Harvard Medical School. He earned his M.B.A. from Harvard Business School.
Dr. Keith Stewart is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine at Mayo Clinic. He currently serves as the Carlson and Nelson Endowed Director of the Center for Individualized Medicine at Mayo Clinic and is recognized as the Vasek and Anna Maria Polak Professor of Cancer Research. His clinical practice and research focuses on genomics and individualized treatment of blood cancers such as multiple myeloma. Dr. Stewart earned his medical degree at Aberdeen University Medical School, United Kingdom, and an MBA degree at the University of Western Ontario.
Justin Odegaard joined OneOme in February 2016 as Laboratory Director. Prior to OneOme, Justin was the Director of Molecular Pathology at Lifecode and is also the Laboratory Director and Senior Medical Director at Guardant Health. Justin received his M.D. and Ph.D. from Stanford University, and trained at Stanford University Hospital in surgical and molecular pathology, where he remains as a part-time Instructor of Pathology.
Jill Davies is Co-Founder and Chief Operating Officer for GeneMatters. Prior to joining GeneMatters in 2016, Jill was Director of Genetics at the Medcan Clinic in Toronto where she was responsible for developing and delivering leading-edge clinical genomics services. With over 15 years of experience in the genetic counseling field, Jill has broad expertise across clinical services, product development, business development and operations. She has a special interest in the role of genomics in primary care and preventive medicine as well as the use of technology to enable access to genomic information and services.
Dr. Wang is a professor in the Department of Molecular Pharmacology and Experimental Therapeutics (MPET) at Mayo Clinic Rochester. Her research involves the application of high-throughput "omics" technologies to identify biomarkers that might help us individualize cancer therapies, understand mechanisms of drug action, and facilitate target identification and drug development. She is also a co-leader of the Mayo Pharmacogenomics Program within the Mayo CIM, where many of the projects involving personalized medicine have been conducted. She is the co-PI for the Mayo-NIH clinical pharmacology T32 training grant and the Associate Director for the Mayo MPET graduate program.
Dr. Weinshilboum received B.A. and M.D. degrees from the University of Kansas, followed by residency training in internal medicine at the Massachusetts General Hospital. He was also a pharmacology Research Associate at the National Institutes of Health (NIH). He began his affiliation with the Mayo Medical School and Mayo Clinic in 1972, where he is presently Professor of Pharmacology and Medicine and Mary Lou and John H. Dasburg Professor of Cancer Genomics Research. He currently directs the Pharmacogenomics Program of the Mayo Center for Individualized Medicine and is co-Principal Investigator of the long-standing US NIH Pharmacogenomics Research Network Center at the Mayo Clinic.